ACBI2 |
ACBI2 : Preferential degrader (PROTAC) of SMARCA2, also degrading SMARCA4
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| SMARCA2 |
|
|
| SMARCA4 |
|
Degrader (PROTAC)
up to 100 nM
Selectivity
In Cell Selectivity Assessment
Potency Assay Off-Target:
ACBI2 degrades SMARCA2 with a > 30-fold window over SMARCA4 in RKO cells (SMARCA2 DC50 = 1 nM, SMARC ...
Potency Cellular
In Vitro
SMARCA2
Mode of Action: Degrader (PROTAC)
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1038/s41467-022-33430-6
SMARCA4
Mode of Action: Degrader (PROTAC)
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1038/s41467-022-33430-6
In Vivo Validations
Mouse
Dose: 5 mg/K
Route of delivery:
Intravenous
Plasma half life:
3.8 h (MRT)
Systemic clearance:
2 mL/min/Kg
Area Under the Curve::
38000 nM*h
Volume of Distribution at Steady-State:
0.47 L/Kg
DOI Reference: 10.1038/s41467-022-33430-6
Dose: 30 mg/Kg
Route of delivery:
Oral
Plasma half life:
6.1 h (MRT)
Area Under the Curve::
50000 nM*h
Bioavailability:
22%
DOI Reference: 10.1038/s41467-022-33430-6
Negative Control Compounds
Chemical Information
| Molecular Formula | C56H68BrFN8O5S |
| SMILEs | Cc1ncsc1-c1ccc([C@H](CC[C@H](C)CCN2CCC(c3ccc4c(c3)n(C3CCCC3)c3nc(=O)c5c(Br)cccc5n43)CC2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)C2(F)CC2)C(C)(C)C)cc1 |
| InChI | InChI=1S/C56H68BrFN8O5S/c1-33(21-26-63-27-22-35(23-28-63)38-18-20-43-45(29-38)65(39-9-6-7-10-39)54-62-51(69)47-41(57)11-8-12-44(47)66(43)54)13-19-42(36-14-16-37(17-15-36)48-34(2)59-32-72-48)60-50(68)46-30-40(67)31-64(46)52(70)49(55(3,4)5)61-53(71)56(58)24-25-56/h8,11-12,14-18,20,29,32-33,35,39-40,42,46,49,67H,6-7,9-10,13,19,21-28,30-31H2,1-5H3,(H,60,68)(H,61,71)/t33-,40+,42-,46-,49+/m0/s1 |
| Molecular weight | 1062.42 Da |
| AlogP | 9.95002 |
| HBond acceptors | 13 |
| HBond donors | 3 |
| Atoms | 140 |
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.